IBRX Stock Analysis: Buy, Sell, or Hold?
IBRX - ImmunityBio, Inc. Common Stock
$7.79
-0.05 (-0.64%)
âŧ
5d:
+2.91%
30d:
+5.27%
90d:
+0.65%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Aug 7, 2026 at $7.64 · last confirmed Aug 21, 2026
Strength: 7.3/10
Get Alerted When IBRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: IBRX is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: IBRX is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: IBRX is currently trading at $7.79, which is considered slightly high relative to its 30-day fair value range of $7.17 to $7.84. From a valuation perspective, the stock is trading at a discount (Forward PE: -61.5) compared to its historical average (132.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, IBRX is in a downtrend. Immediate support is located at $7.42, while resistance sits at $8.27.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.75 (+63.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IBRX is in a downtrend. Immediate support is located at $7.42, while resistance sits at $8.27.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.75 (+63.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$7.17 -
$7.84
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
Protect Your Profits
Holding IBRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 63.7% below Wall St target ($12.75)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.17 -
$7.84
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$7.42
Resistance Level
$8.27
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-61.48
Wall Street Target
$12.75
(+63.7%)
Revenue Growth (YoY)
93.9%
PE vs Historical
-61.5 vs 132.4
CHEAP
Share & Embed Analysis
Last updated: August 23, 2026 5:51 PM ET
Data refreshes hourly during market hours. Next update: 6:51 PM
Data refreshes hourly during market hours. Next update: 6:51 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IBRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 50 HOLD |
|
SMMT
Summit Therapeutics PLC |
STRONG BUY
10 analysts |
$29 | 55 HOLD |
Advanced IBRX Option Strategies
Professional options setups generated by AI based on today's IBRX price and gamma walls.
